We’re launching Lyria 3.5 in Google Flow Music, with advances across musicality, lyrics, vocals, and creative control
deepmind.google·6d ago
AI Engineering
DeepMind Blog·May 16·5 min read
Uncovering repurposed medicines to fight liver fibrosis
TL;DR
Liver fibrosis, a scarring condition leading to serious health issues, lacks effective treatments. Geneticist Gary Peltz utilized Co-Scientist, an AI tool, to identify potential repurposed drugs for this condition.
✦ Why It Matters
Engineers and researchers can leverage AI tools like Co-Scientist to accelerate drug discovery and repurposing efforts.
Key Takeaways
- Investigate existing drugs for potential new applications in liver fibrosis.
- Utilize AI tools like Co-Scientist to enhance drug discovery efforts.
- Focus on drugs that modify gene activity for innovative treatment strategies.
- Collaborate with interdisciplinary teams to leverage diverse expertise in research.
Full Summary
Liver fibrosis, a scarring condition that can progress to cirrhosis, claims over 1.4 million lives annually. Geneticist Gary Peltz at Stanford University employed DeepMind's Co-Scientist to identify existing drugs that could be repurposed for treating this condition.
Peltz asked Co-Scientist to suggest three drug candidates, alongside two he identified from existing literature. In laboratory tests using live human liver cells, Peltz's selections showed no efficacy, while Co-Scientist's candidates included vorinostat, a cancer drug that blocked 91% of a damaging response linked to liver scarring.
This highlights the potential of drugs that modify gene activity rather than targeting specific pathways, suggesting a promising avenue for developing new anti-fibrotic therapies.